Broker Recommendations ResMed, Inc.

Stocks

RMD

US7611521078

Advanced Medical Equipment & Technology

Market Closed - NYSE Other stock markets 01:30:02 22/07/2026 am IST			After hours 05:30:00 am
195.80 ^USD	-1.41%		197.19	+0.71%

21/07	ResMed Earnings Growth Seen Strong as Ventilator Issue Clouds FY27, UBS Says	MT
17/07	RBC Downgrades ResMed to Sector Perform From Outperform, Cuts Price Target to $234 From $276	MT

Broker Recommendations

21/07	ResMed Earnings Growth Seen Strong as Ventilator Issue Clouds FY27, UBS Says	MT
17/07	RBC Downgrades ResMed to Sector Perform From Outperform, Cuts Price Target to $234 From $276	MT
15/07	Mizuho Adjusts Price Target on ResMed to $220 From $235, Maintains Outperform Rating	MT
14/07	Baird Adjusts ResMed Price Target to $217 From $225, Maintains Neutral Rating	MT
13/07	Citigroup Downgrades ResMed to Neutral From Buy, Adjusts Price Target to $235 From $270	MT
13/07	Citi Downgrades ResMed to Neutral From Buy; Price Target is AU$34	MT
10/07	Jefferies Adjusts Price Target on ResMed to $225 From $240	MT
09/07	Jarden Adjusts ResMed's Price Target to AU$40.20 from AU$42.70, Keeps at Overweight	MT
08/07	ResMed's $490 Million Sale of MatrixCare Not Material to Outlook, RBC Says	MT
08/07	Wells Fargo Adjusts Price Target on ResMed to $225 From $227	MT
08/07	RBC Capital Cuts ResMed Price Target to $276 From $321, Maintains Outperform Rating	MT
22/06	KeyBanc Adjusts Price Target on ResMed to $266 From $290, Maintains Overweight Rating	MT
18/06	ResMed Shares Fall After Morgan Stanley Downgrade	MT
17/06	Morgan Stanley Downgrades ResMed to Equalweight From Overweight, Adjusts PT to $230 From $286	MT
15/06	Citigroup Adjusts Price Target on ResMed to $270 From $340, Maintains Buy Rating	MT
01/05	Mizuho Securities Adjusts ResMed Price Target to $235 From $255, Maintains Outperform Rating	MT
01/05	Piper Sandler Adjusts ResMed Price Target to $233 From $275, Maintains Neutral Rating	MT
01/05	RBC Raises Price Target on ResMed to $321 From $314, Keeps Outperform Rating	MT
01/05	Stifel Nicolaus Adjusts ResMed Price Target to $235 From $265	MT
01/05	Jefferies Adjusts ResMed Price Target to $240 From $290	MT
01/05	Wells Fargo Adjusts ResMed Price Target to $227 From $270	MT
01/05	Baird Adjusts ResMed Price Target to $225 From $254	MT
27/04	Morgan Stanley Adjusts Price Target on ResMed to $286 From $310, Maintains Overweight Rating	MT
27/04	KeyBanc Adjusts Price Target on ResMed to $290 From $302, Maintains Overweight Rating	MT
15/04	Baird Adjusts Price Target on ResMed to $254 From $272, Maintains Neutral Rating	MT